GOSSGossamer Bio Inc
GOSS
Gossamer Bio Inc2,958
Mkt Cap
$49.31MVolume
12.8M52W High
$3.8752W Low
$0.1626PE Ratio
-0.27GOSS Fundamentals
Price
$0.2101Prev Close
$0.2009Open
$0.199650D MA
$0.3594Beta
2.19Avg. Volume
6.77MEPS (Annual)
-$0.7455P/B
-0.31Rev/Employee
$299,203.70$774.38
GOSS Investor Alert - Gossamer Bio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit
GOSS Investor Alert - Gossamer Bio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit GOSS Investor Alert - Gossamer Bio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities...
Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire LOS ANGELES, May 22, 2026 LOS ANGELES, May 22, 2026 /PRNewswire/ --The Law...
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure- HBSS
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure- HBSS Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure- HBSS PR Newswire SAN FRANCISCO, May 21, 2026 GOSS Investors with Losses Encouraged to...
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Placebo Response Risks: SueWallSt
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Placebo Response Risks: SueWallSt GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action...
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Clinical Execution Failures: Levi & Korsinsky
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Clinical Execution Failures: Levi & Korsinsky GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class...
The Gross Law Firm Reminds Gossamer Bio, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of June 1, 2026 - GOSS
The Gross Law Firm Reminds Gossamer Bio, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of June 1, 2026 - GOSS The Gross Law Firm Reminds Gossamer Bio, Inc...
GOSS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. (Gossamer or the Company) (NASDAQ: GOSS) and reminds investors of the June 1, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has...
GOSS 2-WEEK DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS
GOSS 2-WEEK DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS GOSS 2-WEEK DEADLINE ALERT: Gossamer Bio...
Gossamer Bio Reports Q1 2026 Results: Full Earnings Call Transcript
read more...
Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support
Gossamer Bio, Inc. (NASDAQ: GOSS) (the Company), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH...
<
1
2
...
>
Compact View
Not available
Not available
Advertisement|Remove ads.
Latest GOSS News
ViewGOSS Investor Alert - Gossamer Bio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit
Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure- HBSS
Advertisement|Remove ads.